# ASP (PPI_H2RA) Study-H2RA Versus PPI for the Prevention of Recurrent UGIB in High-risk Users of Low-dose ASA

> **NCT01408186** · PHASE3 · COMPLETED · sponsor: **Chinese University of Hong Kong** · enrollment: 264 (actual)

## Conditions studied

- Upper Gastrointestinal Bleeding

## Interventions

- **DRUG:** Rabeprazole
- **DRUG:** Famotidine

## Key facts

- **NCT ID:** NCT01408186
- **Lead sponsor:** Chinese University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2015-11
- **Final completion:** 2016-11
- **Target enrollment:** 264 (ACTUAL)
- **Last updated:** 2017-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01408186

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01408186, "ASP (PPI_H2RA) Study-H2RA Versus PPI for the Prevention of Recurrent UGIB in High-risk Users of Low-dose ASA". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01408186. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*